Suppr超能文献

2 型糖尿病 Zucker 糖尿病肥胖大鼠模型中痛性糖尿病周围神经病的纵向研究:基础 G 蛋白活性受损似乎是 6 个月时吗啡低敏性的基础。

Longitudinal study of painful diabetic neuropathy in the Zucker diabetic fatty rat model of type 2 diabetes: impaired basal G-protein activity appears to underpin marked morphine hyposensitivity at 6 months.

机构信息

School of Pharmacy, St Lucia Campus, The University of Queensland, Brisbane, Queensland, Australia.

出版信息

Pain Med. 2011 Mar;12(3):437-50. doi: 10.1111/j.1526-4637.2011.01067.x. Epub 2011 Feb 18.

Abstract

OBJECTIVES

Epidemiological studies in patients with type 1 and type 2 diabetes show that hyperglycemia is associated with the development of long-term microvascular complications, including painful diabetic neuropathy (PDN). However, as the prevalence of type 2 diabetes in humans far exceeds that of type 1, the present study was undertaken as a 22-week longitudinal investigation commencing at 7 weeks of age, to assess the utility of the Zucker diabetic fatty (ZDF) rat model of type 2 diabetes for the study of PDN.

DESIGN

Behavioral methods were used to characterize temporal changes in hindpaw sensitivity as well as morphine potency in these animals. The effect of long-term diabetes on µ-opioid receptor function and mRNA expression levels in the spinal cord was also assessed.

RESULTS

Diabetes developed spontaneously in ZDF rats with marked hyperglycemia (blood glucose levels ≥15 mM) evident by 11 weeks of age, which was maintained until study completion at 29 weeks. In ZDF rats, there was progressive development of mechanical allodynia in the hindpaws such that it was fully developed by 6 months of age. Concurrently, there was temporal loss of opioid sensitivity in these animals such that marked morphine hyposensitivity was evident at 6 months. In the spinal cord, basal G-protein function was significantly impaired at 29 weeks of age, resulting in apparently reduced agonist-stimulated µ-opioid receptor function compared with the prediabetic state.

CONCLUSIONS

Together, our findings suggest that impaired basal G-protein activity underpins morphine hyposensitivity in PDN.

CLINICAL RELEVANCE

Clinical management of diabetic neuropathic pain has been challenging. This study provides a mechanistic explanation regarding the effectiveness, or lack thereof, of opioid analgesia in the treatment of diabetic neuropathic pain.

摘要

目的

1 型和 2 型糖尿病患者的流行病学研究表明,高血糖与长期微血管并发症的发展有关,包括痛性糖尿病神经病变(PDN)。然而,由于 2 型糖尿病在人类中的患病率远远超过 1 型糖尿病,因此本研究作为一项从 7 周龄开始的 22 周纵向研究进行,旨在评估 2 型糖尿病 Zucker 肥胖型(ZDF)大鼠模型在 PDN 研究中的应用。

设计

采用行为学方法来描述这些动物后爪敏感性和吗啡效力的时间变化。还评估了长期糖尿病对脊髓中µ-阿片受体功能和 mRNA 表达水平的影响。

结果

ZDF 大鼠在 11 周龄时出现自发性糖尿病,伴有明显的高血糖(血糖水平≥15mM),直至 29 周研究结束时仍保持高血糖状态。在 ZDF 大鼠中,后爪逐渐出现机械性痛觉过敏,到 6 个月时完全发展。同时,这些动物的阿片敏感性出现时间性丧失,表明在 6 个月时明显出现吗啡低敏性。在脊髓中,29 周时 G 蛋白基础功能显著受损,导致与糖尿病前期状态相比,激动剂刺激的µ-阿片受体功能明显降低。

结论

总之,我们的发现表明,基础 G 蛋白活性受损是 PDN 中吗啡低敏性的基础。

临床相关性

糖尿病性神经病理性疼痛的临床管理一直具有挑战性。本研究提供了一种关于阿片类镇痛药在治疗糖尿病性神经病理性疼痛方面有效性或缺乏的机制解释。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验